Sanofi/Regeneron’s IL-33 blocker meets endpoint in POC study
Sanofis and Regenerons IL-33 blocker REGN3500 met primary Phase II endpoint in asthma patients.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
Researchers and bioethicists to pause germline editing
After the birth of the first genome-edited babies in China, regulators, researchers, and bioethics experts seek ways to ban clinical use of germline editing, in order to protect the innovative field from misuse for human enhancement and side effect-prone application forgene correction and human enhancement.
Karo Pharma acquires Trimb AB
Karo Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (€319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (€141m).
UK biotech to make proteins from carbon dioxide emissions
Deep Branch Biotechnology Ltd. from Nottingham has started a feasibility study with the British energy supplier Drax Group. The technology to be analysed converts carbon dioxide emitted by power stations into protein that could be used for feeding fish and livestock.
GM proponents grill German government
German GM proponents have taken action against discrimination of food products generated by gene editing.
Human cell chip predicts chemotherapy effects
Roche and US company Hesperos Inc have used human cancer and organ cells, placed in a 5-chamber microfluidic chip, to predict chemotherapy safety and efficacy preclinically.
IL-10R-deficient macrophages trigger IBD
Researchers from Israel and the UK have identified how the cytokine IL-23 triggers inflammatory bowel syndrome (IBD), which affects 1.6 million patients annually in the US alone.
Breakthrough in liquid biopsy
German and US researchers have developed a diagnostic technique capable to detect one single circulating tumour cell in one litre of blood.
ADC Therapeutics raise $76m in Series E expansion
Swiss antibody drug conjugate developer ADC Therapeutics SA raised $76m, bringing the total gross proceeds to $276 million in its Series E financing.
Janssen and Genmab in licence option deal
Janssen Biotech Inc has inked a licence option contract with Genmab A/S on its next-generation anti CD38 antibody HexaBody®-CD38 and HexaBody platform technology.